PRECIGEN Investors

Events

Precigen Virtual R&D Day

Jan 24, 2023 at 4:30 PM EST

Precigen's virtual R&D day event showcased complete clinical trial safety and efficacy data from the Phase 1 dose escalation and expansion cohorts for the PRGN-2012 AdenoVerseTM immunotherapy in recurrent respiratory papillomatosis.

Supporting Materials